Meindert Boysen, PharmD
The UK’s National Institute for Health and Care Excellence (NICE) has approved rucaparib (Rubraca) for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy.1
The decision is based on data from the phase III ARIEL3 trial, in which rucaparib led to a median progression-free survival (PFS) of 10.8 months compared with 5.4 months in patients who received placebo, translating to a 68% reduction in the risk of disease progression or death (HR, 0.32; 95% CI, 0.24-0.42]; P
For patients with germline or somatic BRCA
mutations, there was a 77% reduction in the risk of progression or death with rucaparib versus placebo (HR, 0.23; 95% CI, 0.16-0.34; P
“Many people with advanced ovarian cancer experience recurrent disease which requires multiple rounds of chemotherapy. Rucaparib offers patients a new treatment option to help prevent cancer growth, delaying the need for further chemotherapy and the associated side effects,” Meindert Boysen, PharmD, director of the NICE Centre for Health Technology Evaluation, said in a press release.
... to read the full story